Open AccessEpithelial-to-mesenchymal transition of tumor cells: cancer progression and metastasis
Author(s) -
Vasileios Vardas,
Eleni Politaki,
Evangelia Pantazaka,
Vassilis Georgoulias,
Galatea Kallergi
Publication year - 2022
Publication title -
the international journal of developmental biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.837
H-Index - 103
eISSN - 1696-3547
pISSN - 0214-6282
DOI - 10.1387/ijdb.210180gk
Subject(s) - vimentin , circulating tumor cell , epithelial–mesenchymal transition , metastasis , breast cancer , cancer research , cancer , phenotype , mesenchymal stem cell , biology , metastatic breast cancer , cancer cell , pathology , hela , immunohistochemistry , oncology , medicine , immunology , cell culture , gene , biochemistry , genetics
Detection and characterization of circulating tumor cells (CTCs) with an epithelial-to-mesenchymal transition (EMT) phenotype is very important, as it can contribute to the identification of high-risk for relapse and death patients. However, most methods underestimate CTC numbers, owing to their dependence on epithelial markers. In the current study, we evaluated the EMT phenotype in CTCs isolated from breast cancer (BC) patients, using the CellSearch system. Spiking experiments for the evaluation of the specificity and sensitivity of our method were performed using HeLa cells. Sixty-five breast cancer (BC) patients (47 early and 18 metastatic) were enrolled in the study. Vimentin is a mesenchymal marker that indicates tumoral cells acquiring invasive and malignant properties. We studied vimentin (VIM) expression using the extra channel of the CellSearch system and an anti-vimentin antibody conjugated with FITC. In our present results, we reported the percentage of circulating tumor cells that expressed vimentin in early and in metastatic breast cancer patients. Interestingly, the incidence of cells with a CK-VIM+CD45- phenotype was detected in both settings. These cells were detected in 31.4% of CK-negative (11/35) and 82.3% of CK-positive (10/12) early BC patients. The corresponding numbers for metastatic disease were 15.4% (2/13) and 100% (5/5), respectively. Our results suggest that in CTC-negative patients, potentially undetectable tumor cells could be identified using the FDA-approved CellSearch system, based on the (CK-VIM+CD45-)-phenotype, offering additional information regarding metastatic dissemination in cancer patients. Further experiments evaluating more biomarkers are necessary to elucidate the mechanisms that regulate tumorigenesis and metastasis.